Tony Gordon, Ph.D.

Adviser, Raffles Venture Partners
Managing Director (USA) and Laboratory Director (UK), Genesis Genetics

Dr. Gordon is currently the Managing Director for Genesis Genetics USA aboratories, and the Laboratory Director for Genesis Genetics UK laboratories. Dr. Gordon is also a UK State Registered Clinical scientist, with nearly 20 years’ experience in clinical diagnostics and is a Fellow of the Society of Biology.

After obtaining a Ph.D. in Carcinogenesis Research at the University of Nottingham in 1995, Dr. Gordon carried out research for seven years at the Institute of Cancer Research (London, UK) in Molecular Cytogenetics. Between 2002 and 2005, Dr. Gordon ran the microarray divisions of both MWG Biotech and Tecan. In early 2006, Dr. Gordon joined BlueGnome to start their CytoChip microarray product line, a postnatal cytogenetic mental retardation/development delay microarray test. In 2008, Dr. Gordon was fundamental in developing the 24sure product line to bring BlueGnome’s copy number microarray expertise to pre-implantation genetic screening (PGS). In September 2012, BlueGnome was acquired by Illumina for $88M, and integrated into the Reproductive and Genetic Health Business Unit.